Navigation Links
FICCI Proposes Models To Solve Indias Healthcare Crisis

or 10 years for building new facilities and upgrading old ones, extension of exemption to companies creating training in the medical area, industrial status to the sector and soft loans from public sector banks and reduction in custom duty on identified medical equipment.

In addition, FICCI has also called for income tax relief of 15 percent subject to review after a five-year period and enforcement of quality in government hospitals, laboratories and blood banks.

The chamber has suggested attracting private investment in the sector, including foreign direct investment following the PPP route and expanding medical education and training, thereby promoting India as a global hub for quality and affordable healthcare services.

To promote India as a healthcare hub, FICCI has suggested bilateral initiatives like a Joint Economic Trade Committee (JETCO) between Britain and India, business-to-business facilitation for British and Indian companies for medical equipment and mutual recognition of medical degrees among others.


'"/>




Page: 1 2

Related medicine news :

1. Government Organisation Proposes Strict Guidelines For SubStandard Medical Devices
2. Harvard Proposes Drug Disposal Plan
3. San Francisco Mayor Proposes An Alternate Plan For The Uninsured City Residents
4. V P Singh Proposes Doubling Of Medical Seats
5. Govt Proposes, Medicos Disposes, Strike To Intensify
6. Bush Administration Proposes End of Funding of Anti-AIDS Program in Swaziland
7. FDA Proposes Availability of Experimental Drugs
8. FDA Proposes Stringent Warnings Labels for Pain Relievers
9. FSA Proposes Packaging of Fatty Food in Smaller Packs
10. Haryana Government Proposes to Set Up Medical University
11. Australia Proposes Comprehensive Plans to Protect Aboriginal Children from Sexual Abuse
Post Your Comments:
(Date:10/10/2008)..., Oct. 10 /PRNewswire/ -- A senior citizen,soared ...ns in a small,plane. The high-flying adventure was...thrill came from a last-wish program through Silve...iving, where Heden was a patient.,Called Go Wish, ... helped,many realize a special activity at the end...
(Date:10/10/2008)...careful screening for these patients, researcher s... -- Patients coping with metabolic syndrome have a...cancer sometime in their lives, a new study sugges...f three or four diseases, that together can porten...ng a number of cancers," said study co-author Dr. ...
(Date:10/10/2008)...er (BMC) has received a $5,807,469 grant over five...to fund the Boston Claude D. Pepper Older American...of only 11 Pepper Centers in the country. , The...ter Program was established in honor of Claude D. ... his five decades of public service, Pepper was an...
(Date:10/10/2008)...ire/ -- A nationally recognized faculty will,prese...ts with breast,cancer in the multimedia course "Op...iomarkers to Treatment Selection" during National ... for practicing oncologists and other interested,h...est patient care,advances. This accredited course ...
Breaking Medicine News(10 mins):Health News:Deck of Cards is More Than a Game: Integral in Silverado Hospice Care 2Health News:Metabolic Syndrome Raises Colon Cancer Risk 75% 2Health News:Metabolic Syndrome Raises Colon Cancer Risk 75% 3Health News:Boston Medical Center receives $5.8m grant 2Health News:Nationally Recognized Faculty Presents Latest Advances in Care of Patients with Breast Cancer 2
...on called contact dermatitis may benefit from ridd... tomatoes, according to the results of a small stu...ce inflamed, red, itchy, scaly skin when they come.... The reaction is usually associated with an aller...
...ient in the -- depo medroxyprogesterone acetate or... long term. The younger you are when you begin usi...ne-related problems later in life. // From the ..., our bone mass is constantly breaking down and re...
...with testicular cancer may inadvertently increase ...rs.A research team from North Carolina University ...s go down, a high rise in levels of amyloid – the ...ccurs. They suggest that this phenomenon might exp...
...d if all pregnant women stopped smoking, say Austr...rs need much more support and training in helping ...k of having a low birth weight baby, a miscarriage... SIDS - and if women are not able to give up entir...
Other Medicine News:
(Date:10/7/2008)...Study Showed Larazotide Acetate Prevented Immunolo...atients with Celiac Disease, Additional Data Indic...ase, ORLANDO, Fla., Oct. 7 /- Alba T... clinical studies this week at the American,Colleg... Meeting. Data from,study CLIN 1001-004, the first...
(Date:10/7/2008)... FORT COLLINS, Colo., Oct. 7 /- A st...mining embryonic stem cell self-renewal,reported ...tim (recombinant,human serum albumin) was an effec...l culture., The article entitled, "The ground sta... that researchers used Cellastim as a recombinant,...
(Date:10/7/2008)... BERKELEY, Calif., Oct. 7 /- Aerovan...fety data from a Phase I trial of its Aerovant,inh...with no evidence of,local irritancy following asth...This 10 mg dose will be the highest of three doses...g study, which is scheduled to begin early,next ye...
(Date:10/7/2008)... SAN DIEGO, Oct. 7 /- Arde...ay that a poster entitled "RDEA119, a Potent,and H...Dextran Sulfate,Sodium (DSS) -- induced Chronic Co...ege of Gastroenterology (ACG) 2008 Annual Meeting ...ta from a preclinical study of,RDEA119, the Compan...
Breaking Medicine Technology:Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 2Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 3Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 4Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 5Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 6Data Show Aerovance's Aerovant(TM) Inhalation Powder is Well Tolerated in Asthma Patients 2Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting 2Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting 3Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting 4NeoGenomics to Present at the Noble Financial Equity Conference 25367 1NeoGenomics to Present at the Noble Financial Equity Conference 25367 2Courage Center Seeks Applications for Judd Jacobson Memorial Award 25364 1Courage Center Seeks Applications for Judd Jacobson Memorial Award 25364 2REMOXY 28R 29 NDA Filing Accepted by FDA and Priority Review Granted 2827 1REMOXY 28R 29 NDA Filing Accepted by FDA and Priority Review Granted 2827 2REMOXY 28R 29 NDA Filing Accepted by FDA and Priority Review Granted 2827 3New Test Scans Beef for Mad Cow Disease 25361 1New Test Scans Beef for Mad Cow Disease 25361 2
...ESS WIRE)--Jun 21, 2007 - Opexa,Therapeutics, Inc....ent and commercialization of cell therapies, today... Phase I/II,extension clinical trial of the invest...e sclerosis (MS). In this one-year,8-subject exte...,and secondary progressive (SPMS) subjects, Tovaxi...
...ne 21, 2007 - “In anaplastic,astrocytoma, AP...or,to temozolomide,” Prof. Albert Wong, M.D....d on the international Phase,IIb study with the TG...Antisense Pharma. Prof. Wong discussed the results...central nervous system tumors,at the 43rd Annual M...
Other Medicine Technology:Opexa Therapeutics Reports Positive Top-line Data in Phase I/II,Extension Trial with Tovaxin for Multiple Sclerosis 2Opexa Therapeutics Reports Positive Top-line Data in Phase I/II,Extension Trial with Tovaxin for Multiple Sclerosis 3Opexa Therapeutics Reports Positive Top-line Data in Phase I/II,Extension Trial with Tovaxin for Multiple Sclerosis 4Opexa Therapeutics Reports Positive Top-line Data in Phase I/II,Extension Trial with Tovaxin for Multiple Sclerosis 5Antisense Pharma: Promising Phase IIb Results of Targeted Therapy,with AP 12009 in Recurrent Anaplastic Astrocytoma 2Antisense Pharma: Promising Phase IIb Results of Targeted Therapy,with AP 12009 in Recurrent Anaplastic Astrocytoma 3Antisense Pharma: Promising Phase IIb Results of Targeted Therapy,with AP 12009 in Recurrent Anaplastic Astrocytoma 4
...illennium, the newest entry in the Beehive product...monitoring with the technology of the 21st century...igital Video/EEG instrument, providing complete da...that are specialized for epilepsy monitoring appli...
...ncludes 16 electrodes with ball joint, and flexi...r electrode assembly, with 16 female support for b... electrodes. 2 individual electrodes with flexib.... Drill to hole skull. Mounting post. Key to...
Medelec synergy T-EP Developed in collaboration with leading practitioners, for ease of use and an exceptionally high standard of clinical testing, Synergy T-EP harnesses PC Multimedia technology and
Neuropack MEB-2200 evoked potential/EMG measuring system is user friendly Windows NT, Pentium III PC-based EP/EMG measuring system.
Medicine Products: